This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed.
I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief into making the Ocumetics Lens a reality. To now see it safely implanted and beginning to change lives is remarkable. These are the moments we dreamed of.
The early signs are encouraging and give us confidence as we move forward with the next surgical day and complete the first group of patients. The real test lies ahead, as healing continues and vision outcomes begin to emerge.
This achievement is proof that bold ideas, relentless effort, and true teamwork can change the world. And make no mistake—we are changing the world.
Thank you for believing. Thank you for persevering. And thank you for standing shoulder to shoulder with us on this journey. Together, we are making history.
With pride and gratitude,
Dean Burns
President, CEO and Director
Ocumetics Technology
Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including: First-in-human study timing Remaining steps to first-in-human study Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the
Today marks a defining moment in the history of Ocumetics—and in the future of vision restoration worldwide. It is with great pride and anticipation that I share we are now entering the final stages before our First-In-Human (FIH) clinical study for the Ocumetics Lens. This is more than a corporate milestone; it is the beginning
Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:1. Development Update on the Ocumetics IOL2. Remaining steps to first-in-human study3. Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in
Dear Stakeholders, I want to take a moment to update you on our progress with the development of Ocumetics’ accommodative intraocular lens (AIOL), which will soon undergo its first-in-human (FIH) trials. As you know, we are committed to pioneering advanced ophthalmic technologies that will transform the way we treat cataracts and other vision conditions. In
